Heart HealthTrial Tested Green Tea Compound EGCG for Cardiac Amyloidosis
Could a compound in green tea help treat harmful protein buildup in the heart? TAME-AL investigated epigallocatechin-3-gallate, better known as EGCG, in patients with cardiac light-chain amyloidosis. This completed phase 2 trial listed EGCG and placebo as interventions and planned to assess effectiveness and safety. Its main stated measurement compared an MRI-based estimate of protein buildup in the heart before and after treatment. However, the supplied abstract reports no results, participant numbers, doses, treatment duration, or side effects. It therefore cannot establish whether EGCG helped patients or was safe for this condition. This is a study description, not evidence supporting EGCG supplementation. Patients should not replace specialist-directed amyloidosis treatment with green tea or EGCG based on this record. This summary is based on the abstract only.
